The U.S. Food and Drug Administration has recently approved nivolumab to treat patients with advanced metastatic renal cell carcinoma, a form of kidney cancer for patients who have already received an anti-angiogenic therapy. Metastatic renal cell cancer is cancer that has spread beyond its site of origin in the kidney, to other organs in the body. Once renal cell carcinoma has spread to other organs in the body, a patient’s 5-year survival estimate drops to 5-15%.
This is the most common form of kidney cancer in adults and forms in the tissues of the kidney. Beside nephrectomy and radiation-induced ablation of the tumor cell, molecular therapy options like Temsirolimus or everolimus were approved by FDA that has demonstrated overall survival in renal cell cancer. Now with this approval, the list extends by another drug which shows hope to enhance patients’ survival in this disease.…
